Rüdiger P Laubender
Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies
Beigel F, Brand S, Seiderer J, Göke B, Laubender R, Van Steen K, John J, Breiteneicher S, Tillack C, Schnitzler F, Steinborn A, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014; 23:735-44.
Apr 30, 2014Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies
Apr 30, 2014Pharmacoepidemiol Drug Saf 2014; 23:735-44
Beigel Florian, Brand Stephan, Seiderer Julia, Göke Burkhard, Laubender Rüdiger P, Van Steen Kristel, John Jestinah Mahachie, Breiteneicher Simone, Tillack Cornelia, Schnitzler Fabian, Steinborn Anni, Ochsenkühn Thomas
Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
Tillack C, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Maier H, Wetzke M, Ehmann L, Friedrich M, Laubender R, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Brand S. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2013; 63:567-77.
Mar 6, 2013Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
Mar 6, 2013Gut 2013; 63:567-77
Tillack Cornelia, Koburger Maria, Wagner Johanna, Glas Jürgen, Diegelmann Julia, Koglin Sarah, Dombrowski Yvonne, Schauber Jürgen, Wollenberg Andreas, Maier Harald, Wetzke Martin, Ehmann Laura Maximiliane, Friedrich Matthias, Laubender Rüdiger P, Papay Pavol, Vogelsang Harald, Stallhofer Johannes, Beigel Florian, Bedynek Andrea, Brand Stephan
Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease
Beigel F, Ochsenkühn T, Seiderer J, Göke B, Weidinger M, Breiteneicher S, Schnitzler F, Tillack C, Laubender R, Löhr B, Brand S. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Digestion 2011; 85:47-54.
Dec 14, 2011Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease
Dec 14, 2011Digestion 2011; 85:47-54
Beigel Florian, Ochsenkühn Thomas, Seiderer Julia, Göke Burkhard, Weidinger Maria, Breiteneicher Simone, Schnitzler Fabian, Tillack Cornelia, Laubender Rüdiger P, Löhr Beate, Brand Stephan
The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells
Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender R, Auernhammer C. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endocr Relat Cancer 2011; 18:277-85.
Mar 21, 2011The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells
Mar 21, 2011Endocr Relat Cancer 2011; 18:277-85
Zitzmann Kathrin, de Toni Enrico, von Rüden Janina, Brand Stephan, Göke Burkhard, Laubender Rüdiger P, Auernhammer Christoph J
The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants
Glas J, Czamara D, Diegelmann J, Lohse P, Ochsenkühn T, Göke B, Müller-Myhsok B, Weidinger M, Laubender R, Olszak T, Jürgens M, Beigel F, Pfennig S, Tillack C, Seiderer J, Brand S. The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants. PloS one 2010; 5:e14466.
Dec 30, 2010The NOD2 single nucleotide polymorphisms rs2066843 and rs2076756 are novel and common Crohn's disease susceptibility gene variants
Dec 30, 2010PloS one 2010; 5:e14466
Glas Jürgen, Czamara Darina, Diegelmann Julia, Lohse Peter, Ochsenkühn Thomas, Göke Burkhard, Müller-Myhsok Bertram, Weidinger Maria, Laubender Rüdiger P, Olszak Torsten, Jürgens Matthias, Beigel Florian, Pfennig Simone, Tillack Cornelia, Seiderer Julia, Brand Stephan
The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype
Jürgens M, Herrmann K, Lohse P, Göke B, Kreis M, Schnitzler F, Weidinger M, Beigel F, Tillack C, Pfennig S, Wagner J, Wetzke M, Glas J, Seiderer J, Laubender R, Brand S, Ochsenkühn T. The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype. J Gastroenterol 2010; 45:721-31.
Apr 29, 2010The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype
Apr 29, 2010J Gastroenterol 2010; 45:721-31
Jürgens Matthias, Herrmann Karin, Lohse Peter, Göke Burkhard, Kreis Martin E, Schnitzler Fabian, Weidinger Maria, Beigel Florian, Tillack Cornelia, Pfennig Simone, Wagner Johanna, Wetzke Martin, Glas Jürgen, Seiderer Julia, Laubender Rüdiger P, Brand Stephan, Ochsenkühn Thomas
Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis
Jürgens M, Ochsenkühn T, Glas J, Göke B, Lohse P, Tillack C, Schnitzler F, Stallhofer J, Pfennig S, Beigel F, Wetzke M, Wagner J, Seiderer J, Weidinger M, Hartl F, Laubender R, Brand S. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010; 105:1811-9.
Mar 2, 2010Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis
Mar 2, 2010Am J Gastroenterol 2010; 105:1811-9
Jürgens Matthias, Ochsenkühn Thomas, Glas Jürgen, Göke Burkhard, Lohse Peter, Tillack Cornelia, Schnitzler Fabian, Stallhofer Johannes, Pfennig Simone, Beigel Florian, Wetzke Martin, Wagner Johanna, Seiderer Julia, Weidinger Maria, Hartl Franziska, Laubender Rüdiger P, Brand Stephan